BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $6,905,000 | +1.4% | 6,730,000 | +5.7% | 0.54% | -3.7% |
Q4 2020 | $6,807,000 | +1.7% | 6,370,000 | -0.2% | 0.56% | -8.9% |
Q3 2020 | $6,691,000 | -17.3% | 6,385,000 | -3.3% | 0.62% | -25.1% |
Q2 2020 | $8,086,000 | +15.9% | 6,605,000 | -1.9% | 0.83% | +0.1% |
Q1 2020 | $6,977,000 | -29.6% | 6,730,000 | -28.4% | 0.83% | -11.7% |
Q4 2019 | $9,915,000 | +5.1% | 9,405,000 | -1.2% | 0.94% | -4.7% |
Q3 2019 | $9,430,000 | +2.0% | 9,520,000 | +6.7% | 0.98% | -4.8% |
Q2 2019 | $9,242,000 | +3.4% | 8,925,000 | +2.1% | 1.03% | -5.6% |
Q1 2019 | $8,935,000 | +23.2% | 8,745,000 | +19.8% | 1.09% | +4.0% |
Q4 2018 | $7,250,000 | -7.0% | 7,300,000 | -1.2% | 1.05% | -2.3% |
Q3 2018 | $7,792,000 | +3.0% | 7,390,000 | -0.9% | 1.08% | -7.7% |
Q2 2018 | $7,568,000 | -99.9% | 7,455,000 | +5.0% | 1.17% | +9.8% |
Q1 2018 | $6,681,214,000 | +20.1% | 7,100,000 | +27.4% | 1.06% | +18.8% |
Q4 2017 | $5,562,541,000 | +10.6% | 5,575,000 | +12.6% | 0.90% | +2.5% |
Q3 2017 | $5,029,596,000 | – | 4,950,000 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
KBC Group NV | 400,000 | $40,316,000 | 0.15% |
PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |